A randomised, double-blind, placebo-controlled, single and multiple dose, dose-escalation trial of Anti-IL-20 (109-0012) [anti-interleukin-20 monoclonal antibody] 100 mg/vial in psoriatic subjects, followed by an expansion phase.

Trial Profile

A randomised, double-blind, placebo-controlled, single and multiple dose, dose-escalation trial of Anti-IL-20 (109-0012) [anti-interleukin-20 monoclonal antibody] 100 mg/vial in psoriatic subjects, followed by an expansion phase.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Fletikumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Feb 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Dec 2010 Additional lead trial investigator (Rikke Dodge), primary endpoint (Psoriasis Area and Severity Index score 75% response criteria), actual initiation date (Apr 2008) identified as reported by ClinicalTrials.gov.
    • 15 Dec 2010 New source identified and integrated (ClinicalTrials.gov, NCT01261767).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top